Table 3.
DTR-QOL scores
| Week | Dapagliflozin group | DPP4i group | t test | |||
|---|---|---|---|---|---|---|
| n | Mean ± SD | n | Mean ± SD | p value | ||
| Total score | ||||||
| Score | 0 | 123 | 62.9 ± 16.9 | 121 | 65.4 ± 14.8 | 0.21 |
| 24 | 108 | 77.2 ± 15.3 | 119 | 75.9 ± 14.9 | 0.52 | |
| Change from baseline | 24 | 108 |
14.3 ± 15.6 (p < 0.001) |
116 |
10.2 ± 15.6 (p < 0.001) |
0.05 |
| Domain 1 | ||||||
| Score | 0 | 123 | 66.0 ± 21.5 | 123 | 70.6 ± 18.9 | 0.07 |
| 24 | 108 | 81.4 ± 16.6 | 120 | 81.1 ± 16.0 | 0.88 | |
| Change from baseline | 24 | 108 |
15.5 ± 20.8 (p < 0.001) |
119 |
10.3 ± 19.5 (p < 0.001) |
0.05 |
| Domain 2 | ||||||
| Score | 0 | 123 | 57.9 ± 21.8 | 121 | 59.4 ± 18.8 | 0.57 |
| 24 | 109 | 72.6 ± 21.5 | 120 | 71.6 ± 20.7 | 0.72 | |
| Change from baseline | 24 | 109 |
14.1 ± 19.9 (p < 0.001) |
117 |
12.1 ± 20.6 (p < 0.001) |
0.45 |
| Domain 3 | ||||||
| Score | 0 | 123 | 74.5 ± 24.0 | 122 | 74.2 ± 23.6 | 0.94 |
| 24 | 110 | 87.0 ± 19.4 | 120 | 82.8 ± 19.3 | 0.10 | |
| Change from baseline | 24 | 110 |
12.9 ± 23.8 (p < 0.001) |
118 |
9.0 ± 25.3 (p < 0.001) |
0.23 |
| Domain 4 | ||||||
| Score | 0 | 123 | 51.2 ± 17.9 | 121 | 52.3 ± 16.4 | 0.62 |
| 24 | 110 | 62.0 ± 23.4 | 119 | 61.7 ± 22.8 | 0.92 | |
| Change from baseline | 24 | 110 |
10.2 ± 26.5 (p < 0.001) |
116 |
9.4 ± 23.1 (p < 0.001) |
0.81 |
Data are presented as mean ± standard deviation (SD); p values for intragroup comparisons were obtained by using one-sample t test. Intergroup comparisons were performed by using two-sample t test
DPP4i dipeptidyl peptidase inhibitor, DTR-QOL Diabetes Therapy-Related Quality of Life